<DOC>
	<DOCNO>NCT02548650</DOCNO>
	<brief_summary>Dual antiplatelet therapy ( DAPT ) aspirin P2Y12 receptor inhibitor , frequently clopidogrel , represent standard care long-term secondary prevention atherothrombotic event patient myocardial infarction ( MI ) peripheral arterial disease ( PAD ) . However , rate ischemic recurrence remain high . Vorapaxar protease-activated receptor ( PAR ) -1 inhibitor , exert potent inhibition thrombin-mediated platelet aggregation . Patients diabetes mellitus ( DM ) know increase risk recurrent atherothrombotic event , translates bad outcome , despite use standard care therapy . This part due hyperreactive platelet phenotype , characterize DM patient , inadequate response oral antiplatelet agent , include clopidogrel . Therefore , vorapaxar attractive treatment option DM patient prior MI . The pharmacodynamic ( PD ) effect vorapaxar DM patient may differentiate non-DM patient explore . Further , role vorapaxar part dual antithrombotic treatment regimen combine clopidogrel ( stop aspirin ) represent another important area clinical interest . The propose prospective , parallel-design study conduct patient post-MI PAD without DM aim ass pharmacodynamic effect vorapaxar addition standard DAPT aspirin clopidogrel well combination clopidogrel follow aspirin withdrawal .</brief_summary>
	<brief_title>Vorapaxar Add-On Antiplatelet Therapy Patients With Without Diabetes Mellitus</brief_title>
	<detailed_description>Dual antiplatelet therapy ( DAPT ) aspirin P2Y12 receptor inhibitor , frequently clopidogrel , represent standard care long-term secondary prevention atherothrombotic event patient myocardial infarction ( MI ) peripheral arterial disease ( PAD ) . However , rate ischemic recurrence remain high , part due fact platelet signal pathway , thrombin-induced platelet aggregation , continue activate . Vorapaxar novel , orally active , competitive slowly reversible protease-activated receptor ( PAR ) -1 inhibitor , exert potent inhibition thrombin-mediated platelet aggregation . It approve clinical use Food Drug Administration reduction thrombotic cardiovascular event patient history MI peripheral arterial disease . Patients DM know increase risk recurrent atherothrombotic event , translates bad outcome , despite use standard care therapy . This part due hyperreactive platelet phenotype , characterize DM patient , inadequate response oral antiplatelet agent , include clopidogrel . Importantly , DM patient prior MI include TRA 2P trial , vorapaxar reduce primary composite end point 3 year 27 % lead great absolute risk reduction compare without DM . Therefore , vorapaxar attractive treatment option DM patient prior MI . However , date PD effect vorapaxar DM patient may differentiate non-DM patient explore . Further , current trend clinical practice see many patient discontinue aspirin maintain clopidogrel . Hence , role vorapaxar part dual antithrombotic treatment regimen combine clopidogrel ( stop aspirin ) represent another important area clinical interest , order maximize ischemic protection reduce risk bleeding . The propose prospective , parallel-design study conduct patient post-MI PAD without DM aim ass pharmacodynamic effect vorapaxar addition standard DAPT aspirin clopidogrel well combination clopidogrel follow aspirin withdrawal . Pharmacodynamic assessment perform multiple time point , different assay explore multiple pathway platelet aggregation .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Vorapaxar</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients prior MI 2 week 24 month PAD . 2 . On DAPT lowdose aspirin ( 81mg od ) clopidogrel ( 75mg od ) per standardofcare least 14 day . 3 . Age â‰¥ 18 year old . Exclusion criterion : 1 . History acute coronary syndrome previous 2 week . 2 . History stroke , transient ischemic attack , intracranial hemorrhage . 3 . Active pathological bleeding , history bleed event increase risk bleeding . 4 . Known severe hepatic impairment . 5 . Use strong cytochrome P450 3A4 inhibitor ( e.g. , ketoconazole , itraconazole , posaconazole , clarithromycin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , boceprevir , telaprevir , telithromycin conivaptan ) inducer ( e.g. , rifampin , carbamazepine , St. John 's Wort phenytoin ) . 6 . On treatment oral anticoagulant ( vitamin K antagonist , dabigatran , rivaroxaban , apixaban , edoxaban ) . 7 . On treatment antiplatelet agent aspirin clopidogrel past 14 day . 8 . Creatinine clearance &lt; 30 mL/minute . 9 . Platelet count &lt; 80x106/mL 10 . Hemoglobin &lt; 10g/dL 11 . Hemodynamic instability 12 . Pregnant female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>myocardial infarction</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>vorapaxar</keyword>
	<keyword>peripheral arterial disease</keyword>
</DOC>